Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: The HPMPC peripheral cytomegalovirus retinitis trial. The studies of ocular complications of AIDS research group in collaboration with the AIDS clinical trials group

Douglas Jabs, W. R. Freeman, M. Jacobson, R. Murphy, Mark L Van Natta, Curtis L Meinert

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate patients with cytomegalovirus (CMV) retinitis treated with intravenous cidofovir for long-term outcomes. Design: Patients with CMV retinitis enrolled in a randomized, controlled clinical trial of intravenous cidofovir as treatment for retinitis were followed for long-term outcomes, including 21 patients initially enrolled in the deferral group who received cidofovir therapy after progression of retinitis. Setting: Thirteen tertiary care clinics specializing in AIDS care and opthalmology. Participants: Fifty-eight patients with AIDS and small peripheral CMV retinitis lesions. Interventions: Cidofovir 5 mg/kg once weekly for 2 weeks followed by low-dose maintenance cidofovir therapy (3 mg/kg) in 35 patients or high-dose maintenance (5 mg/kg) in 23 patients. Main outcome measures: Time to progression of retinitis, drug toxicities. Results: Median time to progression of retinitis was 2.5 months. Median time to discontinuation of cidofovir because of intolerance was 6.6 months, and did not differ significantly between the two maintenance doses. Median time to discontinuation of cidofovir for intolerance other than probenecid reaction was 16.3 months for patients treated with low-dose maintenance and 5.0 months for patients treated with high-dose maintenance (P=0.021). Proteinuria of 2+ or more occurred at a rate of 1.22/person-year. In patients with sufficient follow-up to determine resolution of proteinuria, 89.9% of episodes resolved, and the median time to resolution was 20 days. Rates of probenecid intolerance and of cidofovir-associated uveitis were 0.35/person-year, and 0.20/person-year, respectively. Conclusion: Although effective for the treatment of CMV retinitis, cidofovir has potential toxicity. Toxicity typically resolves with discontinuation of therapy, but careful attention to both concomitant therapy and monitoring for toxicity is required. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish (US)
Pages (from-to)1571-1581
Number of pages11
JournalAIDS
Volume14
Issue number11
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Cytomegalovirus Retinitis
Acquired Immunodeficiency Syndrome
Clinical Trials
Retinitis
Research
Maintenance
Probenecid
Proteinuria
Therapeutics
cidofovir
Uveitis
Tertiary Healthcare
Drug-Related Side Effects and Adverse Reactions
Randomized Controlled Trials
Outcome Assessment (Health Care)

Keywords

  • AIDS
  • Cidofovir
  • Cytomegalovirus retinitis
  • Nephrotoxicity
  • Uveitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

@article{f8439ce261cd423296f6ac4400731dd9,
title = "Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: The HPMPC peripheral cytomegalovirus retinitis trial. The studies of ocular complications of AIDS research group in collaboration with the AIDS clinical trials group",
abstract = "Objective: To evaluate patients with cytomegalovirus (CMV) retinitis treated with intravenous cidofovir for long-term outcomes. Design: Patients with CMV retinitis enrolled in a randomized, controlled clinical trial of intravenous cidofovir as treatment for retinitis were followed for long-term outcomes, including 21 patients initially enrolled in the deferral group who received cidofovir therapy after progression of retinitis. Setting: Thirteen tertiary care clinics specializing in AIDS care and opthalmology. Participants: Fifty-eight patients with AIDS and small peripheral CMV retinitis lesions. Interventions: Cidofovir 5 mg/kg once weekly for 2 weeks followed by low-dose maintenance cidofovir therapy (3 mg/kg) in 35 patients or high-dose maintenance (5 mg/kg) in 23 patients. Main outcome measures: Time to progression of retinitis, drug toxicities. Results: Median time to progression of retinitis was 2.5 months. Median time to discontinuation of cidofovir because of intolerance was 6.6 months, and did not differ significantly between the two maintenance doses. Median time to discontinuation of cidofovir for intolerance other than probenecid reaction was 16.3 months for patients treated with low-dose maintenance and 5.0 months for patients treated with high-dose maintenance (P=0.021). Proteinuria of 2+ or more occurred at a rate of 1.22/person-year. In patients with sufficient follow-up to determine resolution of proteinuria, 89.9{\%} of episodes resolved, and the median time to resolution was 20 days. Rates of probenecid intolerance and of cidofovir-associated uveitis were 0.35/person-year, and 0.20/person-year, respectively. Conclusion: Although effective for the treatment of CMV retinitis, cidofovir has potential toxicity. Toxicity typically resolves with discontinuation of therapy, but careful attention to both concomitant therapy and monitoring for toxicity is required. (C) 2000 Lippincott Williams and Wilkins.",
keywords = "AIDS, Cidofovir, Cytomegalovirus retinitis, Nephrotoxicity, Uveitis",
author = "Douglas Jabs and Freeman, {W. R.} and M. Jacobson and R. Murphy and {Van Natta}, {Mark L} and Meinert, {Curtis L}",
year = "2000",
doi = "10.1097/00002030-200007280-00013",
language = "English (US)",
volume = "14",
pages = "1571--1581",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis

T2 - The HPMPC peripheral cytomegalovirus retinitis trial. The studies of ocular complications of AIDS research group in collaboration with the AIDS clinical trials group

AU - Jabs, Douglas

AU - Freeman, W. R.

AU - Jacobson, M.

AU - Murphy, R.

AU - Van Natta, Mark L

AU - Meinert, Curtis L

PY - 2000

Y1 - 2000

N2 - Objective: To evaluate patients with cytomegalovirus (CMV) retinitis treated with intravenous cidofovir for long-term outcomes. Design: Patients with CMV retinitis enrolled in a randomized, controlled clinical trial of intravenous cidofovir as treatment for retinitis were followed for long-term outcomes, including 21 patients initially enrolled in the deferral group who received cidofovir therapy after progression of retinitis. Setting: Thirteen tertiary care clinics specializing in AIDS care and opthalmology. Participants: Fifty-eight patients with AIDS and small peripheral CMV retinitis lesions. Interventions: Cidofovir 5 mg/kg once weekly for 2 weeks followed by low-dose maintenance cidofovir therapy (3 mg/kg) in 35 patients or high-dose maintenance (5 mg/kg) in 23 patients. Main outcome measures: Time to progression of retinitis, drug toxicities. Results: Median time to progression of retinitis was 2.5 months. Median time to discontinuation of cidofovir because of intolerance was 6.6 months, and did not differ significantly between the two maintenance doses. Median time to discontinuation of cidofovir for intolerance other than probenecid reaction was 16.3 months for patients treated with low-dose maintenance and 5.0 months for patients treated with high-dose maintenance (P=0.021). Proteinuria of 2+ or more occurred at a rate of 1.22/person-year. In patients with sufficient follow-up to determine resolution of proteinuria, 89.9% of episodes resolved, and the median time to resolution was 20 days. Rates of probenecid intolerance and of cidofovir-associated uveitis were 0.35/person-year, and 0.20/person-year, respectively. Conclusion: Although effective for the treatment of CMV retinitis, cidofovir has potential toxicity. Toxicity typically resolves with discontinuation of therapy, but careful attention to both concomitant therapy and monitoring for toxicity is required. (C) 2000 Lippincott Williams and Wilkins.

AB - Objective: To evaluate patients with cytomegalovirus (CMV) retinitis treated with intravenous cidofovir for long-term outcomes. Design: Patients with CMV retinitis enrolled in a randomized, controlled clinical trial of intravenous cidofovir as treatment for retinitis were followed for long-term outcomes, including 21 patients initially enrolled in the deferral group who received cidofovir therapy after progression of retinitis. Setting: Thirteen tertiary care clinics specializing in AIDS care and opthalmology. Participants: Fifty-eight patients with AIDS and small peripheral CMV retinitis lesions. Interventions: Cidofovir 5 mg/kg once weekly for 2 weeks followed by low-dose maintenance cidofovir therapy (3 mg/kg) in 35 patients or high-dose maintenance (5 mg/kg) in 23 patients. Main outcome measures: Time to progression of retinitis, drug toxicities. Results: Median time to progression of retinitis was 2.5 months. Median time to discontinuation of cidofovir because of intolerance was 6.6 months, and did not differ significantly between the two maintenance doses. Median time to discontinuation of cidofovir for intolerance other than probenecid reaction was 16.3 months for patients treated with low-dose maintenance and 5.0 months for patients treated with high-dose maintenance (P=0.021). Proteinuria of 2+ or more occurred at a rate of 1.22/person-year. In patients with sufficient follow-up to determine resolution of proteinuria, 89.9% of episodes resolved, and the median time to resolution was 20 days. Rates of probenecid intolerance and of cidofovir-associated uveitis were 0.35/person-year, and 0.20/person-year, respectively. Conclusion: Although effective for the treatment of CMV retinitis, cidofovir has potential toxicity. Toxicity typically resolves with discontinuation of therapy, but careful attention to both concomitant therapy and monitoring for toxicity is required. (C) 2000 Lippincott Williams and Wilkins.

KW - AIDS

KW - Cidofovir

KW - Cytomegalovirus retinitis

KW - Nephrotoxicity

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=0033816267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033816267&partnerID=8YFLogxK

U2 - 10.1097/00002030-200007280-00013

DO - 10.1097/00002030-200007280-00013

M3 - Article

C2 - 10983644

AN - SCOPUS:0033816267

VL - 14

SP - 1571

EP - 1581

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 11

ER -